1	Diagnostic accuracy of the Point-of-Care Standard G6PD test TM (SD Biosensor) for
2	Glucose-6-phosphate dehydrogenase deficiency: a systematic review of the literature
3	
4	Short title: Diagnostic accuracy of a Point-of-Care Standard G6PD test
5	
6	Juan Camilo Martínez ^{1*} , Viviana Vélez-Marín ¹ , Mary Lopez-Perez ² , Daniel Felipe Patiño ¹ ,
7	Ivan D. Florez ^{1,3,4,5*}
8	
9	¹ Unit of evidence and deliberation for decision making UNED, Medical Research Institute,
10	School of Medicine, University of Antioquia UdeA
11 12	² Centre for Medical Parasitology, Department for Immunology and Microbiology, Faculty of Health and Medical Sciences, University of Copenhagen, Copenhagen, Denmark
13 14	³ Department of Pediatrics, School of Medicine, University of Antioquia UdeA, Av. St 70 No. 52-21 Medellin Colombia
15	⁴ School of Rehabilitation Science, McMaster University, Hamilton, Canada
16	⁵ Pediatric Intensive Care Unit, Clinica Las Americas-AUNA, Medellin, Colombia
17	*Corresponding author: E-mail: <u>ivan.florez@udea.edu.co</u> . School of medicine,
18	University of Antioquia UdeA, Av. St 70 No. 52-21, Medellin, Colombia.

19 Abstract

20	Glucose-6-Phosphate Dehydrogenase deficiency (G6PDd) is a common genetic
21	enzymopathy that can induce hemolysis triggered by various factors, including some anti-
22	malarial drugs. Although many Point-of-Care (PoC) tests, such as STANDARD G6PD TM
23	manufactured by SD biosensor (StandG6PD-BS), are available to detect G6PDd, its pooled
24	diagnostic test accuracy (DTA) remains unknown. To estimate the DTA of StandG6PD-BS
25	at various thresholds of G6PDd, we conducted a systematic review with a DTA meta-
26	analysis, searching EMBASE, MEDLINE, and SciELO databases up to June 30, 2023. We
27	included studies measuring G6PD activity using StandG6PD-BS (reference test) and
28	spectrophotometry (gold standard) in patients suspected of having G6PDd. We assessed the
29	risk of bias (RoB) of the studies using the QUADAS-2 tool and the certainty of evidence
30	(CoE) with the GRADE approach. Our approach included the estimation of within-study
31	DTA, a random-effect bivariate meta-analysis to determine the pooled sensitivity and
32	specificity for 30%, 70%, and 80% enzyme levels' thresholds, and a graphical analysis of
33	the heterogeneity using crosshair and Confidence Regions on receiver operating
34	characteristic (ROC) space plots. After screening 2,407 reports, we included four studies
35	with 7,864 participants covering all thresholds. Two studies had high RoB in QUADAS-2
36	domains 2 and 3, and the others had low RoB. We also found low, moderate, and high
37	heterogeneity at the 30%, 70%, and 80% thresholds, respectively. The pooled sensitivity
38	was 99.1% (95%CI 96.9-99.7%, CoE: high), 95.7% (92.0-97.0%, high), and 90% (78.0-
39	96.5%, low) for 30%, 70%, and 80% thresholds, respectively. The pooled specificity was
40	97.4% (95%CI 95.0; 98.4%, high); 92.9% (85.0-96.4%, high); and 89.0% (76.0-96.0%,

41 moderate) for 30%, 70%, and 80% thresholds, respectively. In conclusion, StandG6PD-BS
42 is a PoC test with high sensitivity and specificity to detect G6PDd at different thresholds.

43 Author summary

44 Glucose-6-Phosphate Dehydrogenase deficiency (G6PDd) is a common genetic disease that 45 can induce the destruction of red blood cells leading to anemia triggered by various factors. 46 including some drugs used for malaria treatment. After a literature search in different 47 databases up to January 31, 2023, we pooled diagnostic test accuracy of the Point-of-Care 48 (PoC) STANDARD G6PDTM test manufactured by SD biosensor (StandG6PD-BS) used 49 to identify the G6PDd. Although two of the four studies included showed a high Risk of 50 Bias related to the index test and the reference standard domains of the QUADAS-2 tool, 51 the pooled sensitivity and specificity for 30%, 70%, and 80% enzyme levels' thresholds 52 were around 90%, with better sensitivity and specificity values for the 30% threshold (99.1% and 97.4%) compared with 70% (95.7% and 92.9%) and 80% (90% and 89%) 53 54 threshold. We found low, moderate, and high heterogeneity at the 30%, 70%, and 80% 55 thresholds. In conclusion, StandG6PD-BS is a PoC test with high sensitivity and specificity 56 to detect G6PDd at different thresholds.

57 Keywords: systematic review, metanalysis, Glucose-6-phosphate dehydrogenase, malaria,
58 Point-of-Care test, STANDARD G6PDTM.

59 Introduction

60	Glucose-6-phosphate dehydrogenase deficiency (G6PDd) is a genetic disorder linked to the
61	X chromosome, with hemizygous males and homozygous females having a deficient
62	activity phenotype (< 30% of enzyme levels). In contrast, heterozygous females may have a
63	normal (> 80%) or intermediate activity phenotype (30% to 80% enzyme level) (1).
64	Individuals with deficient activity may experience hemolytic episodes triggered by intrinsic
65	or extrinsic factors such as medications or certain foods (2). G6PDd is the most common
66	enzymopathy in humans, with variable frequencies and distinctive region-specific
67	distribution (3). It is particularly common in malaria-endemic regions (1,4), with an
68	estimated frequency of 8%- 10% (~350 to 400 million cases per year) and over 200
69	identified genetic polymorphisms (5). This overlapping is attributed to the protective effect
70	of G6PDd against malaria (1).
71	Malaria caused by <i>Plasmodium vivax</i> is geographically widespread and counts for most
72	cases outside Africa, particularly in the Americas and South-East Asia (6). Primaquine
73	(PQ) and the novel tafenoquine (TQ) are the only two approved drugs for treating hepatic
74	stages and are used for the radical cure of uncomplicated malaria by <i>P. vivax</i> (5,7).
75	However, these drugs may precipitate hemolytic crises in individuals with G6PDd (1,5,7),
76	with the severity of the reaction being proportional to the dose of the medication received
77	and the enzyme genotype (5,7). To ensure safe administration of these drugs, the World
78	Health Organization (WHO) recommends testing for G6PDd in those requiring treatment
79	with PQ (7). This could be achieved by using Point-of-Care (PoC) tests to determine G6PD

80 activity before administering PQ and TQ, as has been recommended by multiple studies81 (8).

82	Several tests are currently available to determine the G6PD activity, but they have different
83	performance (9,10). Since the gold standard for G6PD measurement (spectrophotometry) is
84	not suitable for PoC testing, qualitative tests have been developed with variable diagnostic
85	performance and operational characteristics (11-13). While those tests discriminate
86	between normal and deficient G6PD activity and therefore are sufficient to guide PQ
87	treatment, they may not be dependable enough to prevent drug-induced hemolysis with the
88	introduction of TQ. Consequently, more reliable diagnostic tests are required, and one of
89	such test is the semi-quantitative assay STANDARD G6PD TM (SD biosensor, Republic of
90	Korea), an enzymatic colorimetric assay intended to aid the detection of G6PDd (14). This
91	PoC test provides a numeric measurement of G6PD enzymatic activity and total
92	hemoglobin (Hb) concentration in fresh capillary and venous human whole blood
93	specimens (14) and allows classification of the G6PD activity as deficient, intermediate, or
94	normal according to thresholds provided by the manufacturer (14).
95	Despite the recommendation for PoC quantitative or semi-quantitative testing before
96	administering antimalarial treatment, there is only one synthesis of the diagnostic test
97	accuracy (DTA) of the STANDARD G6PD TM test manufactured by SD Biosensor
98	(StandG6PD-BS) (15) in which the authors pooled the individual results of various studies
99	without a complete systematic review approach, risk of bias, and certainty of evidence
100	assessment. In this systematic review and metanalysis, we estimated the pooled DTA of the
101	StandG6PD-BS for different thresholds of G6PD activity.

102

103 Materials and methods

104 **Protocol and registration**

105 This systematic review and DTA meta-analysis were conducted and reported following the

106 Preferred Reporting Items for Systematic Reviews and Meta-analyses of DTA Studies

107 (PRISMA-DTA) guidelines. The protocol was registered in the PROSPERO database

108 (CRD42022311085).

109 Search and study selection

110 Two authors (JCM, VVM) performed a structured search in MEDLINE (via PubMed),

111 EMBASE, and SciELO databases on August 2nd, 2022, and updated it on January 31, 2023,

and on June 30, 2023 without language or date restrictions. Our search strategy is outlined

113 in Table S1. We included prospective or retrospective studies that measured G6PD activity

114 levels using the reference standard enzymatic test (spectrophotometry G6PD assay) and the

reference test (StandG6PD-BS). The studies must have reported enough data to calculate

116 diagnostic performance measures, i.e., true positives (TP), true negatives (TN), false

positives (FP), and false negatives (FN), for at least one threshold (30%, 70%, and 80%) of

118 G6PD activity.

119 Using Rayyan software (Rayyan QCRI, Qatar) (16), two authors screened titles and

120 abstracts retrieved from searches, and only those records considered eligible by both

121 reviewers were retrieved in full texts for the next stage. The same authors (JCM, VVM)

122 reviewed the potentially eligible full texts, independently and in duplicate, based on the

123 pre-specified inclusion criteria. Those studies considered eligible by both reviewers were

124 included. Disagreements were resolved by consensus among the reviewers and with the

- 125 participation of a third reviewer if needed (MLP, IDF).
- 126 The same authors (JCM, VVM) independently and in duplicate extracted the data from the
- 127 included studies using a prespecified data extraction form designed in Google Forms
- 128 (Google LLC, US), which was discussed and piloted among the research team. For each
- 129 study, we extracted the following information: first author, year of publication, title,
- 130 population, data for every threshold recommended by the manufacturer (SD biosensor®),
- 131 number of participants, age (mean and standard deviation), sex, type of blood sample
- 132 (venous or capillary), and the data needed for 2x2 contingency tables (TP, FP, FN, and
- 133 TN). Disagreements in the data extraction process were discussed between the reviewers.

134 **Risk of bias assessment and certainty of the evidence**

- 135 Two authors (JCM, VVM) independently assessed the Risk of Bias (RoB) for the included
- 136 studies using the Quality Assessment of Diagnostic Accuracy Studies 2 (QUADAS-2) tool
- 137 (17). The QUADAS-2 instrument evaluates the RoB of DTA studies with four domains
- 138 (patient selection, index test, reference standard, and flow and timing), judging each as
- 139 high, low, or unclear in risk of bias and concerns regarding applicability. The authors
- 140 discussed any disagreements and resolved them through consensus.
- 141 We assessed the Certainty of Evidence (CoE) using the GRADE framework for DTA
- 142 systematic reviews (18,19). This approach evaluates four criteria: RoB (judged using the
- 143 QUADAS-2 assessment), indirectness, inconsistency, publication bias and impression, and
- 144 rates the certainty of the evidence in high, moderate, low, and very low.

145 Statistical analysis

146 We used R Software and the package mada (version 4.1.2, The R Foundation for Statistical 147 Computing) for the statistical analyses (20) and the GRADE Pro GDT platform (McMaster 148 University 2015, developed by EvidencePrime, Inc) for creating the Summary of Findings 149 (SoF) tables. First, we calculated sensitivity, specificity, positive likelihood ratio (+LR), 150 negative likelihood ratio (-LR), and diagnostic odds ratio (DOR) at every threshold. The 151 cut-off recommended for the StandG6PD-BS test manufacturer is a valuable tool for 152 therapeutic decisions because enzyme levels define the use of specific treatment. Thus, 153 enzymatic levels above 30% allow using PQ and other drugs at specific doses; levels above 154 70% allow using TQ and any PQ treatment schedule; and levels above 80% define a normal 155 G6PD activity. Then, we fitted the type of blood sample data at each threshold with the 156 *Reistma* model (21), a bivariate random-effect meta-analysis. With this approach, we 157 calculated the pooled sensitivity, specificity, +LR, and -LR and their corresponding 95% 158 confidence intervals (95% CI) utilizing model estimations. We used data only from female 159 participants at 70% and 80% thresholds. We pooled the results for venous blood samples 160 because the combined capillary samples were too small and not measured in all the studies. 161 For between-studies heterogeneity, we used visual inspection of forest plots for DTA 162 pooled measures, crosshair plots (sensitivity vs. false positive rate), confidence regions in 163 the *Receiver Operating Characteristic* (ROC) space, evaluating the overlap in the 164 confidence intervals, and *chi-square* test for homogeneity (*p*-values <0.05 were considered 165 significant, and therefore as with heterogeneity). We did not obtain enough studies to fit the 166 sensitivity analysis models as stated in the registered protocol.

167 **Results**

168 Search results

169 We obtained 2,818 records and after removing duplicates, we screened 2,407 unique

170 reports and identified nine potentially eligible studies. After the full-text assessment, we

171 excluded five and included four studies that met the inclusion criteria for qualitative and

172 quantitative synthesis (**Figure 1**).

Figure 1. PRISMA flow diagram indicating the process of inclusion and exclusion ofstudies.

175 Included and excluded studies

176 We excluded five studies (Table S2) because of the different populations, reference tests,

177 or outcomes (i.e., neither provides DTA measures nor data to calculate them; **Table S2**).

178 **Table 1** summarizes the characteristics of the four included studies (22–25). These studies

179 were conducted in the United States (U.S.) (22,25), United Kingdom (U.K.) (22), Brazil

180 (23), Bangladesh (24), and Thailand (25). In total, they included 3,122 (30% thresholds of

181 the StandG6PD-BS), 2,371 (70%), and 2,371 (80%) participants for each test analysis,

182 respectively. All studies were cross-sectional DTA, two included healthy adults (\geq 18 years

183 old) (22,25), one included participants older than two years (23), and three studies included

184 individuals with known G6PD status (23–25). The reference test used in all the studies was

185 spectrophotometry for the G6PD kit (Pointe Scientific).

186 **Table 1.** Characteristics of included studies

188 Risk of Bias (RoB)

- 189 Two studies were judged as high (24,25), and two as low RoB in domain one (22,23)
- 190 (patient selection) of the QUADAS-2 tool. One study was judged high (24), two unclear
- 191 (22,25), and one low RoB in domain four (23) (flow and timing). All studies had low RoB
- and applicability concerns in domains two and three (reference test and standard). This
- 193 information is presented as a table and diagram using the QUADAS-2 tool resources
- 194 (**Figure 2**).

195

196 Figure 2. RoB summary judgements about each included study using QUADAS-2 tool.

197

198 Diagnostic test accuracy from primary studies and pooled data

199 Sensitivities and specificities from primary studies are presented in Figure 3. Sensitivity 200 ranged from 91% to 99%, whereas specificities were from 89% to 97% for 30% and 80% 201 thresholds, respectively. Figure 3 displays the crosshair plot (sensitivity vs. false positive 202 rates) for the three thresholds. Positive and negative LR from studies are presented in 203 Figure S1. Pooled DTA measures for each G6PD activity threshold are described (Table 204 2). Pooled results showed high DTA measures for all the thresholds being better for lower 205 than the highest threshold. Positive and negative LR ranged from 8.2 to 35.3 and 0.009 to 206 0.106. The CoE for sensitivity and specificity was high for 30% and 70% thresholds, but 207 for 80% threshold sensitivity was low and specificity was moderate due to concerns in the 208 RoB, indirectness, inconsistency, and imprecision (See Table S3).

209	We found low, moderate, and high heterogeneity in the results for the 30%, 70%, and 80%
210	thresholds, respectively (Figure 4 and 5).
211	
212	Table 2. Pooled DTA values for each threshold defined by Standard TM G6PD (SD
213	Biosensor) test.
214	
215	Figure 3. Pooled Sensitivity and Specificity for Standard TM G6PD (SD Biosensor) in
216	venous blood samples.
217	
218	
219	Figure 4. Crosshair plot for each threshold defined by the Standard TM G6PD (SD
220	Biosensor) test.
221	
222	Figure 5. SROC curve (bivariate model) for different Standard G6PD (SD Biosensor)

thresholds in venous blood samples.

224 **Discussion**

- In this systematic review, we included four studies evaluating 7,864 patients and found that
- 226 StandG6PD-BS is a semi-quantitative PoC test with high sensitivity and specificity values
- to detect G6PDd at the different G6PD activity thresholds recommended by the
- 228 manufacturer (30%, 70%, and 80%). The test showed better performance and CoE for 30%
- and 70%, compared with the 80% threshold. Likewise, the heterogeneity in the results was
- low, moderate, and high at 30%, 70%, and 80% thresholds, respectively.

231 The included studies were conducted in both high and low-middle-income countries, and 232 participants were predominantly healthy adults with or without known G6PD status. This 233 allows the decision-makers to assess the potential impact of implementing the StandG6PD-234 BS PoC test in the general population, particularly for uncomplicated malaria by *P. vivax*. 235 The evidence suggests that introducing this test in tropical and subtropical malaria-endemic 236 countries with *P. vivax* high transmission regions would be both feasible and desirable and 237 could provide numerous benefits (5,7,26). For instance, a recent study in Brazil (26) found 238 that combining TQ treatment with the StandG6PD-BS test improved the response to radical 239 cure treatment by enhancing adherence, reducing relapses, and increasing protection against 240 new P. vivax infections.

The literature describes factors related to lower test accuracy that may not be explained just by the PoC test performance. A recent controlled study suggested that the StandG6PD-BS test performed well in venous blood, exhibiting good repeatability and inter-laboratory reproducibility (27). However, the same study found that the reliability of the test was poor in discriminating between intermediate and low G6PD activities in lyophilized samples

246	(27), emphasizing the need for further research in field-based scenarios. This study found
247	similar estimates for sensitivity and specificity as reported by Addisu et al. (15). However,
248	our work is the first to conduct a complete systematic review approach through a
249	comprehensive search and selection, a random model meta-analysis, risk of bias
250	assessment, and certainty of evidence using the GRADE approach and following the
251	methods recommended by the Cochrane collaboration.
252	In our energies we needed only regults of you out blood securities because other secures
232	In our approach, we pooled only results of venous blood samples because other sources,
253	such as capillary and lyophilized blood, provided limited results due to small sample sizes
254	in the studies and differences in the specimen collection and lyophilization methods.
255	Nevertheless, some evidence suggests that capillary and lyophilized blood samples could
256	drive less accuracy in the PoC test results (22,27–29).
257	In the included studies, only one (25) used frozen venous blood to run the StandG6PD-BS
258	test showing slightly less DTA than the fresh venous blood samples (25). This could be due
259	to the small number of participants, the specimen collection, or the storage method. An
260	alternative cause is the study population (Thailand), which carries the G6PDd Mahidol
261	phenotype with moderate enzymatic activity (30-70%) However the StandG6PD-BS
262	sensibilities and specificities at those levels are still around 90% (22,27,30).
263	The current evidence strongly supports the implementation of the PoC test for G6PD
264	activity. At the individual level, it will enable the safe treatment of more patients with
265	deficient and intermediate G6PD activity, diminishing the risk of recurrent malaria and
266	acute hemolytic anemia (5,7,31,32). At the healthcare systems level, it could reduce the
267	associated costs and the burden on transfusion services by reducing the number of

268 hemolytic crises caused by PO or TO in individuals with unknown G6PD status and 269 malaria treatment (5,7,31,33). Additionally, this could impact parasite transmission rates 270 when combined with other interventions (5,7,31). Given that up to 50% of the patients with 271 P. vivax malaria may experience relapses (5.7), administering radical cure with PO or TO is 272 essential for stopping morbidity-related and community transmission (5,7,26,32). 273 Our work has several strengths. This systematic review with meta-analysis is the first to 274 evaluate the DTA of the StandG6PD-BS test. Moreover, we followed state-of-the-art 275 methodologies for conducting DTA studies, as recommended by the Cochrane Handbook 276 for Systematic Reviews of Diagnostic Test Accuracy (34). We prepared the final report of 277 this review following the recommendations by the PRISMA-DTA statement (35). We also 278 provided information on the pooled sensitivity and specificity for each threshold, which can 279 facilitate decision-making in different clinical scenarios.

280 We also recognize some limitations. First, the number of studies was low, preventing us 281 from performing additional analyses, such as sensibility analysis. Additionally, the quality 282 of some studies was not optimal, although our analysis is robust enough to show adequate 283 pooled DTA measures for venous blood samples. Future studies using capillary and 284 lyophilized blood, along with field-based studies, are needed to determine the appropriate 285 usage of this test. A study on barriers and facilitators for G6PD test implementation (36) 286 identified three main barriers: perceived low risk of hemolysis, wrong perception of P. 287 *vivax* malaria as a benign condition, and the cost of routine testing as part of the healthcare 288 attention of malaria patients. A study conducted in Brazil on the operational challenges 289 associated with pragmatic G6PD testing (37) found that the StandG6PD-BS PoC test was 290 well accepted by both healthcare professionals and patients and can be performed at

- 291 malaria treatment units in the Brazilian Amazon to inform treatment decisions with PQ.
- However, the authors found limitations linked to technical and cultural aspects that should
- be addressed when expanding screening to larger areas (37).

294 Conclusion

- 295 StandG6PD-BS is a PoC test with high sensitivity and specificity to detect G6PDd at the
- different thresholds recommended by the manufacturer (30%, 70%, and 80%).
- 297 Implementing this kind of test in malaria-endemic areas can lead to early diagnosis of
- 298 G6PDd, help to prevent hemolytic episodes triggered by PQ or TQ, and potentially impact
- 299 malaria transmission.

300 Acknowledgments

301	We acknowledge Dr Lina Gaviria	(Haematologist, Universidad de Antiog	uia, Colombia),

- 302 for their contribution to the conceptualization of this study; Marina Figueira, and Camilo
- 303 Manchola (Global Health Strategies), Jonathan Novoa (Medicines for Malaria Venture),
- 304 and Jamil Barton and Reina Jara (Program for Appropriate Technology in Health) for their
- 305 contribution in this study.

306

307 Data Availability Statement

308 The data are available on request from the authors.

309 Funding

- 310 This work and its authors (JCM, VVM, MLP, DPL, IDF) were supported, in whole part, by
- 311 the Bill & Melinda Gates Foundation through a sub-agreement with Global Health
- 312 Strategies (GHS) as part of the project: "Cost-effectiveness of Tafenoquine in the radical
- 313 cure of *Plasmodium vivax* malaria" (Grant Number OPP1194815). Under the grant
- 314 conditions of the Foundation, a Creative Commons Attribution 4.0 Generic License has
- 315 already been assigned to the Author Accepted Manuscript version that might arise from this
- 316 submission (https://globalhealthstrategies.com). MLP is supported by Independent
- 317 Research Fund Denmark (grant 013400123B; https://dff.dk/en). The funders had no role in
- 318 study design, data collection and analysis, decision to publish, or preparation of the
- 319 manuscript.

320 **Competing interest**

- 321 The authors declare no competing interests.
- 322 Author's contributions
- 323 Conceptualization: JCM, IDF.
- **Data curation**: JCM, VVM.
- 325 Formal analysis: JCM, VVM, IDF, MLP
- **Funding acquisition:** IDF, DFP.
- 327 Investigation: IDF, DFP, JCM, VVM.
- 328 Methodology: JCM, VVM.
- 329 **Project administration:** JCM.
- 330 **Resources:** IDF.
- 331 Software: JCM
- 332 Supervision: IDF, DFP.
- 333 Visualization: JCM, VVM.
- 334 Writing original draft: VVM, JCM.
- 335 Writing review & editing: JCM, VVM, DFP, IDF, MLP.

- 336 ORCID IDs:
- 337 JCM: ttps://orcid.org/0000-0001-6420-7797
- 338 VVM: https://orcid.org/0000-0002-9430-3912
- 339 MLP https://orcid.org/0000-0002-9876-0248
- 340 DFP: https://orcid.org/0000-0003-4030-4255
- 341 IDF: https://orcid.org/0000-0002-0751-8932

343 **References**

- 1. Howes RE, Battle KE, Satyagraha AW, Baird JK, Hay SI. Chapter Four G6PD
- 345 Deficiency: Global Distribution, Genetic Variants and Primaquine Therapy. In: Hay
- 346 SI, Price R, Baird JKBT-A in P, editors. The Epidemiology of Plasmodium vivax
- 347 [Internet]. Academic Press; 2013. p. 133–201. Available from:
- 348 https://www.sciencedirect.com/science/article/pii/B9780124078260000047
- Bancone G, Chu CS. G6PD Variants and Haemolytic Sensitivity to Primaquine and
 Other Drugs. Front Pharmacol. 2021;12:638885.
- 351 3. Nkhoma ET, Poole C, Vannappagari V, Hall SA, Beutler E. The global prevalence
- 352 of glucose-6-phosphate dehydrogenase deficiency: A systematic review and meta-
- analysis. Blood Cells, Mol Dis [Internet]. 2009;42(3):267–78. Available from:

354 https://www.sciencedirect.com/science/article/pii/S1079979609000059

- 4. Howes RE, Dewi M, Piel FB, Monteiro WM, Battle KE, Messina JP, et al. Spatial
- 356 distribution of G6PD deficiency variants across malaria-endemic regions. Malar J
- 357 [Internet]. 2013;12(1):418. Available from: https://doi.org/10.1186/1475-2875-12-
- 358 418

5. Chu CS, White NJ. The prevention and treatment of Plasmodium vivax malaria.
PLoS Med. 2021;18(4 April):1–21.

- 361 6. World Health Organization (WHO). World Malaria Report 2023. 2023.
- 362 7. Organización Mundial de la Salud OMS. Testing for G6PD deficiency for safe use of
- 363 primaquine in radical cure of P. vivax and P. ovale malaria Policy brief. Geneva;
- 364 2016.

365	8.	Malaria Policy Advisory Committee Meeting. Point-of-care G6PD testing to support
366		safe use of primaquine for the treatment of vivax malaria. Geneve; 2015.
367	9.	LaRue N, Kahn M, Murray M, Leader BT, Bansil P, McGray S, et al. Comparison of
368		Quantitative and Qualitative Tests for Glucose-6-Phosphate Dehydrogenase
369		Deficiency. Am Soc Trop Med Hyg [Internet]. 2014;91(4):854–61. Available from:
370		https://www.ajtmh.org/view/journals/tpmd/91/4/article-p854.xml
371	10.	Espino FE, Bibit J-A, Sornillo JB, Tan A, von Seidlein L, Ley B. Comparison of
372		Three Screening Test Kits for G6PD Enzyme Deficiency: Implications for Its Use in
373		the Radical Cure of Vivax Malaria in Remote and Resource-Poor Areas in the
374		Philippines. PLoS One [Internet]. 2016;11(2):1–12. Available from:
375		https://doi.org/10.1371/journal.pone.0148172
376	11.	Osorio L, Carter N, Arthur P, Bancone G, Gopalan S, Gupta SK, et al. Performance
377		of BinaxNOW G6PD Deficiency Point-of-Care Diagnostic in P. vivax-Infected
378		Subjects. Am Soc Trop Med Hyg [Internet]. 2015;92(1):22–7. Available from:
379		https://www.ajtmh.org/view/journals/tpmd/92/1/article-p22.xml
380	12.	Ley B, Bancone G, von Seidlein L, Thriemer K, Richards JS, Domingo GJ, et al.
381		Methods for the field evaluation of quantitative G6PD diagnostics: a review. Malar J
382		[Internet]. 2017;16(1):361. Available from: https://doi.org/10.1186/s12936-017-
383		2017-3
384	13.	Brito MAM, Peixoto HM, de Almeida ACG, de Oliveira MRF, Romero GAS,
385		Moura-Neto JP, et al. Validation of the rapid test Carestart(tm) G6PD among malaria
386		vivax-infected subjects in the Brazilian Amazon. Rev Soc Bras Med Trop [Internet].
387		2016 Jul 1 [cited 2022 Oct 21];49(4):446-55. Available from:

388		http://www.scielo.br/j/rsbmt/a/5pRMqmmgJbk7LvHNBwPXCVD/?lang=en
389	14.	PATH. G6PD Operational Research Community of Practice. 2022.
390	15.	Adissu W, Brito M, Garbin E, Macedo M, Monteiro W, Mukherjee SK, et al.
391		Clinical performance validation of the STANDARD G6PD test: A multi-country
392		pooled analysis. PLoS Negl Trop Dis [Internet]. 2023 Oct 12;17(10):e0011652.
393		Available from: https://doi.org/10.1371/journal.pntd.0011652
394	16.	Ouzzani M, Hammady H, Fedorowicz Z, Elmagarmid A. Rayyana web and
395		mobile app for systematic reviews. Syst Rev [Internet]. 2016;5(1):210. Available
396		from: http://dx.doi.org/10.1186/s13643-016-0384-4
397	17.	Whiting P, Rutjes A, Westwood M, Mallett S, Deeks J, Reitsma J, et al. QUADAS-
398		2: A Revised Tool for the Quality Assessment of Diagnostic Accuracy Studies. Ann
399		Intern Med [Internet]. 2011;155(8):529–36. Available from:
400		https://www.acpjournals.org/doi/abs/10.7326/0003-4819-155-8-201110180-00009
401	18.	Schünemann HJ, Mustafa RA, Brozek J, Steingart KR, Leeflang M, Murad MH, et
402		al. GRADE guidelines: 21 part 1. Study design, risk of bias, and indirectness in
403		rating the certainty across a body of evidence for test accuracy. J Clin Epidemiol
404		[Internet]. 2020 Jun 1;122:129–41. Available from:
405		https://doi.org/10.1016/j.jclinepi.2019.12.020
406	19.	Schünemann HJ, Mustafa RA, Brozek J, Steingart KR, Leeflang M, Murad MH, et
407		al. GRADE guidelines: 21 part 2. Test accuracy: inconsistency, imprecision,
408		publication bias, and other domains for rating the certainty of evidence and
409		presenting it in evidence profiles and summary of findings tables. J Clin Epidemiol

- 410 [Internet]. 2020 Jun 1;122:142–52. Available from:
- 411 https://doi.org/10.1016/j.jclinepi.2019.12.021
- 412 20. Doebler P. mada: Meta-Analysis of Diagnostic Accuracy [Internet]. 2020. Available
- 413 from: https://cran.r-project.org/package=mada
- 414 21. Reitsma JB, Glas AS, Rutjes AWS, Scholten RJPM, Bossuyt PM, Zwinderman AH.
- 415 Bivariate analysis of sensitivity and specificity produces informative summary
- 416 measures in diagnostic reviews. J Clin Epidemiol [Internet]. 2005 Oct 1;58(10):982–
- 417 90. Available from: https://doi.org/10.1016/j.jclinepi.2005.02.022
- 418 22. Pal S, Myburgh J, Bansil P, Hann A, Robertson L, Gerth-Guyette E, et al. Reference

419 and point-of-care testing for G6PD deficiency: Blood disorder interference,

- 420 contrived specimens, and fingerstick equivalence and precision. PLoS One.
- 421 2021;16(9 September):1–24.
- 422 23. Zobrist S, Brito M, Garbin E, Monteiro WM, Clementino Freitas S, Macedo M, et al.
- 423 Evaluation of a point-of-care diagnostic to identify glucose-6-phosphate
- 424 dehydrogenase deficiency in Brazil. PLoS Negl Trop Dis [Internet]. 2021;15(8):1–
- 425 21. Available from: https://doi.org/10.1371/journal.pntd.0009649
- 426 24. Alam MS, Kibria MG, Jahan N, Thriemer K, Hossain MS, Douglas NM, et al. Field
- 427 evaluation of quantitative point of care diagnostics to measure glucose-6-phosphate
- 428 dehydrogenase activity. PLoS One [Internet]. 2018;13(11):1–13. Available from:
- 429 https://doi.org/10.1371/journal.pone.0206331
- 430 25. Pal S, Bansil P, Bancone G, Hrutkay S, Kahn M, Gornsawun G, et al. Evaluation of
- 431 a Novel Quantitative Test for Glucose-6-Phosphate Dehydrogenase Deficiency:

432		Bringing Quantitative Testing for Glucose-6-Phosphate Dehydrogenase Deficiency
433		Closer to the Patient. Am J Trop Med Hyg [Internet]. 2018;100(1):213-21.
434		Available from: https://www.ajtmh.org/view/journals/tpmd/100/1/article-p213.xml
435	26.	Nekkab N, Lana R, Lacerda M, Obadia T, Siqueira A, Monteiro W, et al. Estimated
436		impact of tafenoquine for Plasmodium vivax control and elimination in Brazil: A
437		modelling study. PLoS Med. 2021;18(4):1-19.
438	27.	Ley B, Satyagraha AW, Kibria MG, Armstrong J, Bancone G, Bei AK, et al.
439		Repeatability and reproducibility of a handheld quantitative G6PD diagnostic. PLoS
440		Negl Trop Dis. 2022;16(2):1–17.
441	28.	Drain PK, Hyle EP, Noubary F, Freedberg KA, Wilson D, Bishai WR, et al.
442		Evaluating Diagnostic Point-of-Care Tests in Resource-Limited Settings. Lancet
443		Infect Dis. 2014 Mar;14(3):239–49.
444	29.	Jameel F, Alexeenko A, Bhambhani A, Sacha G, Zhu T, Tchessalov S, et al.
445		Recommended Best Practices for Lyophilization Validation 2021 Part II: Process
446		Qualification and Continued Process Verification. AAPS PharmSciTech.
447		2021;22(8).
448	30.	Aung TH, Suansomjit C, Tun ZM, Hlaing TM, Kaewkungwal J, Cui L, et al.
449		Prevalence of G6PD deficiency and diagnostic accuracy of a G6PD point-of-care test
450		among a population at risk of malaria in Myanmar. Malar J. 2023;22(1):143.
451	31.	Garcia LS. Malaria. Clin Lab Med. 2010;30(1):93-129.
452	32.	Llanos-Cuentas A, Manrrique P, Rosas-Aguirre A, Herrera S, Hsiang MS.
453		Tafenoquine for the treatment of Plasmodium vivax malaria. Expert Opin

454 Pharmacother. 2022;23(7):759-68. 455 Peixoto HM. Brito MAM. Romero GAS. Monteiro WM. de Lacerda MVG. de 33. 456 Oliveira MRF. Rapid diagnostic test for G6PD deficiency in Plasmodium vivax-457 infected men: a budget impact analysis based in Brazilian Amazon. Trop Med \& Int 458 Heal [Internet]. 2017;22(1):21–31. Available from: 459 https://onlinelibrary.wiley.com/doi/abs/10.1111/tmi.12800 460 34. Cochrane Handbook for Systematic Reviews of Diagnostic Test Accuracy 461 Cochrane Training [Internet]. [cited 2022 Aug 14]. Available from: 462 https://training.cochrane.org/handbook-diagnostic-test-accuracy 463 35. McInnes MDF, Moher D, Thombs BD, McGrath TA, Bossuyt PM, Group and the 464 P-D. Preferred Reporting Items for a Systematic Review and Meta-analysis of 465 Diagnostic Test Accuracy Studies: The PRISMA-DTA Statement. JAMA [Internet]. 466 2018 Jan 23;319(4):388–96. Available from: 467 https://doi.org/10.1001/jama.2017.19163 468 36. Ley B, Thriemer K, Jaswal J, Poirot E, Alam MS, Phru CS, et al. Barriers to routine 469 G6PD testing prior to treatment with primaguine. Malar J. 2017;16(1):1–10. 470 37. Brito-Sousa JD, Murta F, Vitor-Silva S, Sampaio V, Mendes M, Souza B, et al. 471 Quantitative G6PD Deficiency Screening in Routine Malaria Diagnostic Units in the 472 Brazilian Amazon (SAFEPRIM): An Operational Mixed-Methods Study. Pathogens. 473 2022;11(11).

Figure 1. PRISMA flow diagram indicating the process of inclusion and exclusion of

studies.



Figure 2. Risk of Bias summary judgements about each included study using

QUADAS-2 tool. QUADAS-2: Quality Assessment of Diagnostic Accuracy Studies version

2



Figure 3. Pooled Sensitivity and Specificity for Standard[™] G6PD (SD Biosensor) in venous blood samples. Forest Plot for displaying the sensitivity and specificity per study according to specific thresholds with their corresponding 95% CI

Sensitivities			Specificities		
medRxiv preprint doi: https://doi.org/10.1101/2024.02.10.24 (which was not certified by peer review) is the author It is made availab	4302326; this version posted Febru n/funder, who has granted medRxi ile under a CC-BY 4.0 International	ary 11, 2024. The co v a license to display license .	pyright holder for this pr the preprint in perpetuit	reprint ty.	0.99 [0.98, 0.99]
Pal - US (2018)	•	0.99 [0.95, 1.00]	Pal - US (2018)	→	0.97 [0.94, 0.98]
Pal - Thailand (2018)	•-	0.99 [0.92, 1.00]	Pal - Thailand (2018)	•	0.94 [0.88, 0.97]
Alam (2018)	→	0.98 [0.86, 1.00]	Alam (2018)	•	0.99 [0.94, 1.00]
Pal (2021)		0.99 [0.92, 1.00]	Pal (2021)	H•+	0.96 [0.95, 0.98]
	0.86 0.90 0.97			0.88 0.94 1.0	0

30% Threshold

70% Threshold



80% Threshold

Sensitivities			Specificities			
Zobrist (2021)	— —	0.67 [0.55, 0.78]	Zobrist (2021)	-	0.98 [0.96, 0.98]	
Pal - US (2018)		0.95 [0.90, 0.98]	Pal - US (2018)		0.86 [0.82, 0.90]	
Pal - Thailand (2018)	H	0.96 [0.91, 0.99]	Pal - Thailand (2018)		0.74 [0.60, 0.85]	
Alam (2018)	H	0.95 [0.87, 0.96]	Alam (2018)	⊢ −−1	0.80 [0.66, 0.89]	



Figure 4. Crosshair plot for each threshold defined by the Standard[™] G6PD (SD Biosensor) test. DTA combined compared thresholds for Standard[™] G6PD (SD Biosensor) in venous blood samples The crosshair plot colors correspond to thresholds: blue to 30%, green to 70%, and red to 80%.



Figure 5. SROC curve (bivariate model) for different thresholds for Standard[™]
G6PD (SD Biosensor) in venous blood samples. Summary receiver operating
characteristic (SROC) curve summarizing sensitivity and false positive rates according to
the three thresholds, with the corresponding 95% confidence contour.







False Positive Rate

Table 1. Characteristics of included studies

First Author	Year	Study type	Countries	Study context	Inclusion criteria	Sample type	Threshold	N for test operative characteristics (2x2 tables)					Reference (index) test	Gold Standard	Observation	Funding
								TP	FN	FP	TN	Total				
Pal (21)	2021	Cross- sectional DTA	U.S. (three clinical centers) U.K.	Healthy volunteers blood denors in different clinical centers	Healthy adults, ≥ 18 years old. They signed written informed consent.	Venous	30%	56	0	26	708	790	STANDARD TM Spectrophotometry for 7 G6PD G6PD using the kit (SD Biosensor) Pointe Scientific	Spectrophotometry for G6PD using the kit Pointe Scientific	None	UK's FCDO, Bill & Melinda Gates fdn.
							70%	82	1	49	658	790				
							80%	85	16	58	631	790				
Zobrist (22)	2021	Cross- sectional DTA	Brazil	Febrile patients seeking care at the Manana (924) and Porto Velho clinics (812)	Participants ≥ 2 years old plus 69 belonged through an enriched sample for G6PD known status.	Venous	30%	56	0	23	1583	1662	STANDARD™ G6PD (SD Biosensor)	Spectrophotometry for G6PD using the kit Pointe Scientific	Measurement of temperature and humidity data at the time of testing that can affect PoC enzymatic activity test	UK's FCDO, Bill & Melinda Gates fdn., the National Institutes of Health
							70%	31	1	31	848	911				
							80%	41	20	21	829	911				
Alam (23)	2018	Cross- sectional DTA	Bangladesh	Participants were recruited in the Chittagong Hill Tracts districts (south- eastern)	Convenience sample from a cohort of adult with known G6PD status.	Venous	30%	30	0	0	76	106	STANDARD TM Spectrophotometry fo G6PD G6PD using the kit (SD Biosensor) Pointe Scientific	Spectrophotometry for G6PD using the kit Pointe Scientific	Review of test results changes in blood samples stored at room temperature (24 to 26°C) and 4°C.	Wellcome Trust, n Australian DFAT, Bill & Melinda Gates fdn.
							70%	48	3	8	47	106				
							80%	58	3	9	36	106				
Pal (24)	2018	Cross- sectional DTA	U.S.	Healthy volunteers blood donors in two clinical centers (New York and Miami)	Healthy adults, ≥ 18 years old, with an African American origin.	Fresh venous blood	30%	84	0	10	320	414	STANDARD TM Spectrophotometry for G6PD G6PD using the kit (SD Biosensor) Pointe Scientific (for Thailand, the Trinity Biotech assay was used)	Spectrophotometry for G6PD using the kit Pointe Scientific (for Thailand, the Trinity Biotech assay was used).	None	UK's DFID, Bill & Melinda Gates fdn., MORU-Wellcome Trust
							70%	105	5	9	295	414				
							80%	115	6	40	253	414				
		Cross- sectional DTA	Thailand	Participants attended two clinical centers located north and south of Mae Sot that serve a migrant population of Burman and Karen ethnic groups.	Adults with known GOPD h status joined the study to achieve a convenience sample.	Frozen venous blood	30%	54	0	5	91	150				
							70%	96	5	9	40	150				
							80%	103	4	11	32	150	1			

Abbreviations: TP: True Positives; FN: False Negatives; FP: False Positives; TN: True Negatives; G6PD: Glucose-6-Phosphate Dehydrogenase; DTA: Diagnostic Test Accuracy; U.S.: United States of America; U.K.: United Kingdom; FCDO: Foreign, Commonwealth & Development Office; fdn.: foundation; DFAT Department of Foreign Affairs and Trade, DFID: Department for International Development; MORU: Mahidol Oxford Tropical Medicine Research Unit Table 2. Pooled DTA values for each threshold defined by StandardTM G6PD (SD Biosensor) test.

	G6PD activity threshold	Sensitivity (95%CI) & CoE	Specificity (95%CI) & CoE	+LR (95%CI)	-LR (95%CI)	
	30%	99.1% (96.9%-99.7%) (4 studies, 3122 participants)	97.4% (95.2-98.4%) (4 studies, 3122 participants)	35.3	0.009	
		High ⊕⊕⊕⊕	High ⊕⊕⊕⊕	(20.7-60.5)	(0.003-0.031)	
	70%	95.7% (92.9-97.4%) (4 studies, 2371 participants)	92.8% (85.8-96.5%) (4 studies, 2371 participants)	13.2	0.046 (0.030-0.073)	
		High ⊕⊕⊕⊕	High ⊕⊕⊕⊕	(6.8-26.5)		
medRxiv preprint do (which was not	: https://doi.org/10.1101 certified by peer revie 80% It is	/2024.02.10.24302326; this version posted Febru w) is the author/funder, who has granted medRxiv made available under a COBH 4.61 Meridational	ary 11, 2024. The copyright holder for this preprin a license to display the preprint in perpetuity license	8.2	0.106	
		Low @@OO	Moderate ⊕⊕⊕⊖	(4.1-16.0)	(0.049-0.227)	

Abbreviations: CI: confidence interval, LR: likelihood ratio, +: positive, -: negative, CoE: Certainty of the Evidence